Zurcher Kantonalbank Zurich Cantonalbank Purchases 10,086 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 27.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 47,359 shares of the biotechnology company’s stock after acquiring an additional 10,086 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in BioCryst Pharmaceuticals were worth $284,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Braidwell LP boosted its stake in BioCryst Pharmaceuticals by 92.1% in the third quarter. Braidwell LP now owns 5,362,980 shares of the biotechnology company’s stock worth $37,970,000 after purchasing an additional 2,571,100 shares in the last quarter. Deerfield Management Company L.P. Series C lifted its position in BioCryst Pharmaceuticals by 148.6% during the 3rd quarter. Deerfield Management Company L.P. Series C now owns 3,286,000 shares of the biotechnology company’s stock worth $23,265,000 after buying an additional 1,964,000 shares in the last quarter. Rice Hall James & Associates LLC lifted its position in BioCryst Pharmaceuticals by 21.5% during the 3rd quarter. Rice Hall James & Associates LLC now owns 2,275,638 shares of the biotechnology company’s stock worth $16,112,000 after buying an additional 402,674 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund bought a new stake in shares of BioCryst Pharmaceuticals during the third quarter valued at approximately $2,719,000. Finally, Jump Financial LLC increased its holdings in shares of BioCryst Pharmaceuticals by 371.5% in the third quarter. Jump Financial LLC now owns 404,913 shares of the biotechnology company’s stock valued at $2,867,000 after purchasing an additional 319,037 shares in the last quarter. 85.88% of the stock is owned by institutional investors and hedge funds.

BioCryst Pharmaceuticals Stock Performance

Shares of BioCryst Pharmaceuticals stock opened at $4.45 on Monday. BioCryst Pharmaceuticals, Inc. has a 52 week low of $4.03 and a 52 week high of $8.96. The firm has a fifty day moving average of $4.93 and a two-hundred day moving average of $5.46. The stock has a market capitalization of $918.17 million, a price-to-earnings ratio of -3.77 and a beta of 1.96.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its earnings results on Monday, February 26th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.04). The business had revenue of $93.40 million during the quarter, compared to analysts’ expectations of $89.19 million. As a group, research analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.69 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Needham & Company LLC reiterated a “buy” rating and issued a $12.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Wednesday, April 10th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $13.83.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.